首頁
Poseida Therapeutics, Inc.

3月 2026Poseida Therapeutics, Inc.的市場佔有率分析

Poseida Therapeutics is a clinical-stage biopharmaceutical company developing cell and gene therapies with the capacity to cure cancers and genetic diseases.

健康 > 生物技術和製藥

域名poseida.com

成立年份2014

僱員201 - 500

年度營收$100M - $200M

Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc.（包含公司地區）

poseida.com

查看更多網站流量與參與度資訊

Poseida Therapeutics, Inc.截至 3月 2026 的總收入為 100M - 200M

Poseida Therapeutics, Inc. 熱門網域產生的總收入

Poseida Therapeutics, Inc. 熱門網域 3 年內的總收入

Poseida Therapeutics, Inc. 熱門網域的總收入

poseida.com100M - 200M

透過銷售情報查看更多內容

Poseida Therapeutics, Inc.的熱門網域總造訪量

了解Poseida Therapeutics, Inc.市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

子公司細目

poseida.com3.8K

透過銷售情報查看更多內容

Poseida Therapeutics, Inc.的熱門網域平均造訪時長

分析Poseida Therapeutics, Inc.參與度指標。

過去 3 個月平均造訪時長

子公司細目

poseida.com00:00:26

透過銷售情報查看更多內容

Poseida Therapeutics, Inc.的熱門網域平均頁面瀏覽量

了解Poseida Therapeutics, Inc.如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

子公司細目

poseida.com1.77

透過銷售情報查看更多內容

Poseida Therapeutics, Inc.按網域劃分的熱門競爭對手

3月 2026的熱門類似網站，依相似度排名

daiichisankyo.com公司名Daiichi Sankyo僱員> 10001總部日本, Tokyo年度營收> $1B訪問總量176.6K健康 > 生物技術和製藥

使用的熱門技術Poseida Therapeutics, Inc.

这些是Poseida Therapeutics, Inc.顶级域名使用的行业网站技术

付費廣告 (5)

DoubleClick

轉換與分析 (4)

Google Analytics

小工具 (4)

Twemoji

行動裝置 (2)

Meta Viewport

更多技術

9

檢視所有

新聞與訊號來自Poseida Therapeutics, Inc.

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞Basbaum leaves Poseida Therapeutics, Inc. as Senior Vice President of Business Development.Prior to joining MBX Biosciences, Ms. Basbaum served as Senior Vice President of Business Development at Poseida Therapeutics, where she was a member of the Executive Committee and led strategic partnerships and corporate transactions totaling more than $10 billion in potential value, and she played a key role in the company's sale to Roche for up to $1.5 billion.

新聞Poseida Therapeutics, Inc. is developing CAR-T programmes for solid tumours and autoimmune diseases.Poseida is also working on CAR-T programmes for solid tumours and autoimmune diseases.

新聞Roche acquired Poseida Therapeutics, Inc. for $1.5B on Nov 26th '24.Poseida (Nasdaq: PSTX) announced Nov. 26 that it had entered into a merger agreement to be acquired by Roche (OTCMKTS: RHHBY) in a transaction worth up to $1.5 billion.